Antibody Discovery Global Market Report 2024

The antibody discovery market size has grown rapidly in recent years. It will grow from $8.09 billion in 2023 to $8.96 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed in the historical period can be attributed to factors such as a surge in investment for drug discovery, increased funding for research and development activities, and the presence of various healthcare research centers and academic institutions.

The antibody discovery market size is expected to see rapid growth in the next few years. It will grow to $13.21 billion in 2028 at a compound annual growth rate (CAGR) of 10.2%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing demand for antibody drug discovery services and platforms, a surge in funding for the development of novel technologies, a growing demand for precision therapeutics, and the broadening utilization of antibodies beyond their conventional therapeutic roles. Major trends expected in the forecast period encompass increased research and development activities, a growing demand for monoclonal antibodies, increased adoption of advanced technologies, a rising demand for targeted therapeutics, and the development of novel antibody formats.

The antibody discovery market is poised for significant growth due to the increasing demand for precision therapeutics, also known as personalized therapeutics. This approach tailors medical treatments to individual patient characteristics, enhancing effectiveness. Antibody discovery plays a pivotal role in precision therapeutics by facilitating the development of targeted therapies such as monoclonal antibodies, which interact precisely with disease-related molecules or cells. Notably, in January 2023, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% of therapeutic NMEs classified as personalized medicines. This underscores the pivotal role of precision therapeutics in driving the antibody discovery market's growth.

Leading players in the antibody discovery market are investing in cutting-edge technologies to streamline and enhance antibody development processes. One notable innovation is the emergence of AI-based computational antibody drug discovery platforms, which leverage artificial intelligence and computational techniques to expedite antibody identification and optimization. For example, in October 2023, SwiftPharma BV introduced an AI-driven antibody discovery platform. This platform integrates artificial intelligence, big data, machine learning, and phage display techniques to swiftly predict high-specificity and high-affinity antibody-antigen binding. By mimicking natural language processing, this approach generates diverse antibody variations, enabling comprehensive antibody library creation with unprecedented efficiency. This advanced system significantly accelerates the discovery of potential antibody drugs.

In November 2021, Twist Bioscience Corporation, a leading US-based biotechnology company, completed the acquisition of Abveris for an undisclosed sum. This strategic integration of the Abveris discovery platform aligns seamlessly with Twist's objectives, enhancing and expanding its capabilities in biopharmaceutical antibody development, especially in the field of mouse-based discovery and screening. Abveris, also based in the US, specializes in antibody discovery services.

Major companies operating in the antibody discovery market report are Danaher Corporation, Eurofins Scientific, Sartorius AG, Charles River Laboratories, Bruker Corporation, WuXi Biologics, Genmab A/S, Evotec, Cambrex corporation, ChemPartner, Aragen life science pvt ltd, Genscript Technology Corporation, Biocytogen, Alcami corporation.Inc, Twist Bioscience, BioDuro-Sundia, Fairjourney Biologics S.A, Harbour BioMed, Rockland Immunochemicals, Creative Biolabs, Synbio technologies, ImmunoPrecise, Ablexis, Myrio Therapeutics, Antibody Solutions, MabSilico.

North America was the largest region in the antibody discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Antibody discovery is the process of identifying and developing antibodies, which are proteins generated by the immune system to defend the body against harmful substances such as bacteria and viruses. Antibodies, also known as immunoglobulins, play a vital role in the immune response by recognizing and binding to specific molecules known as antigens.

The primary methods employed in antibody discovery include phage display, hybridoma, and others. Phage display is a molecular biology technique utilized for the study and selection of peptides or proteins, typically antibodies, that exhibit high affinity to a target of interest. This method is widely applied in antibody discovery to generate and select antibodies with specific binding properties. Various types of antibodies, including humanized antibodies, human antibodies, chimeric antibodies, and murine antibodies, find application among end users in the pharmaceutical and biotechnology industries, research laboratories, and academic institutions.

The antibody discovery research report is one of a series of new reports that provides antibody discovery market statistics, including the antibody discovery industry's global market size, regional shares, competitors with an Antibody discovery market share, detailed antibody discovery market segments, market trends and opportunities, and any further data you may need to thrive in the antibody discovery industry. This antibody discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antibody discovery market includes revenues earned by entities by providing services such as antigen identification, immunization, antibody generation, screening, and characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The antibody discovery market also includes sales of antibody libraries, phage display kits, antigen proteins, and antibody screening platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.